Trump’s war on drug prices and climate science: dilemma of market transformation

Trump has stepped up pressure on pharmaceutical companies to lower U.S. drug prices and extended the response period by 60 days after the initial demand was not met. He has contacted executives at 17 companies, including Eli Lilly and international giants such as Sanofi and Novartis, aiming to tie U.S. drug prices to the world's lowest prices. Meanwhile, Trump’s directive to retire the $750 million carbon monitoring satellites OCO-2 and OCO-3 are facing strong congressional opposition for disrupting climate science and breaching funding rules.